Editorial
|
|
|
Pharmacovigilance is mission impossible for pharmaceutical companies
|
|
|
Marketing Authorisations
|
|
|
For a few selected patients
|
|
|
|
|
|
|
|
Do not include gliptins in your prescribing list
|
|
|
|
|
|
|
Better to stick with proven treatments
|
|
|
|
Adverse Effects
|
|
|
Pharmacovigilance revealed risk factors
|
|
|
|
|
|
During pregnancy non-drug methods should be tried first
|
|
|
|
|
|
Do not mix milligrams and millilitres
|
|
|
|
|
|
Women were given appetite suppressants during pregnancy
|
|
|
|
|
|
Mostly faster administration rate
|
|
|
|
|
|
List of adverse effects growing
|
|
|
|
|
|
|
Alarming increase in consumption
|
|
|
|
Reviews
|
|
|
Androgen suppression for symptomatic disease
|
|
|
|
Outlook
|
|
|
One more reason to reduce drug use
|
|
|
|
|
|
|
A key contributor to the development of new drugs
|
|
|
|
|
|
Ceruse: a skin-lightening cosmetic at the king's court
|
|
|
|